Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

1

Revenue 2017

Humira

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Humira was produced by AbbVie and Eisai.

AbbVie/Allergan merger faces renewed public opposition despite divestments

AbbVie/Allergan merger faces renewed public opposition despite divestments

AbbVie. They also highlighted AbbVie’s use of controversial “rebate walls” around its blockbuster immunology products – including Humira and Skyrizi – which the groups say “lead to higher prescription drug prices” and

After FDA refusal, Takeda builds case for subcutaneous Entyvio

After FDA refusal, Takeda builds case for subcutaneous Entyvio AbbVie’s TNF blocker Humira (adalimumab) in a head-to-head trial. ... Analysts at GlobalData have previously suggested that having two formulations of vedolizumab will allow Takeda to compete strongly against well-established ulcerative colitis drugs

Cosentyx, Entresto drive topline growth for Novartis in Q4

Cosentyx, Entresto drive topline growth for Novartis in Q4 However, in head-to-head trials with both AbbVie’s  Humira (adalimumab) and  Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market

AbbVie creates new aesthetics division amid Allergan takeover

AbbVie creates new aesthetics division amid Allergan takeover Ahead of the upcoming patent loss of AbbVie’s ageing blockbuster Humira, the Allergan acquisition and now the subsequent division of its aesthetics business will give AbbVie more space to focus

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Takeda’s subcutaneous Entyvio formulation faces FDA rejection Takeda showcased a study of the intravenous formulation of Entyvio earlier this year, which positioned it head-to-head with AbbVie’s ageing immunology blockbuster Humira (adalimumab). ... In comparison, 22.5% of patients who received Humira every

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics